

WHAT IS CLAIMED IS:

1. An isolated polypeptide comprising an amino acid sequence at least 75% identical to a sequence selected from the group consisting of SEQ ID NO: 5 2, 4 and 6.
2. The isolated polypeptide of claim 1 wherein said polypeptide is at least 90% identical to the sequence selected from the group consisting of SEQ ID NO: 2, 4, and 6.  
10
3. The isolated polypeptide of claim 1 wherein said polypeptide is at least 95% identical to the sequence selected from the group consisting of SEQ ID NO: 2, 4, and 6.
4. The isolated polypeptide of claim 1 wherein said polypeptide has the amino acid sequence selected from the group consisting of SEQ ID NO: 15 2, 4 and 6.
5. The isolated polypeptide of claim 1 wherein said polypeptide is found in an organism selected from the group consisting of group A streptococci, 20 group B streptococci, and *Staphylococcus aureus*.
6. The isolated polypeptide of claim 5 wherein the group A streptococcal organism is *Streptococcus pyogenes*.  
25
7. The isolated polypeptide of claim 5 wherein the group B streptococcal organism is *Streptococcus agalactiae*.

8. The isolated polypeptide of claim 1 wherein said polypeptide has a sequence at least 25% identical to the amino acid sequence of the Sp36 protein of *Streptococcus pneumoniae*.

5        9. An isolated polynucleotide comprising a sequence coding for a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8.

10      10. The isolated polynucleotide of claim 9 wherein said polynucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3 and 5.

15      11. An antibody specific for a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8.

12. The antibody of claim 11 wherein said antibody is a monoclonal antibody.

20      13. A genetically engineered cell producing the antibody of claim 12.

14. A vector comprising the polynucleotide of claim 9.

15. A vector comprising the polynucleotide of claim 10.

25      16. A genetically engineered cell expressing the polypeptide coded for by the polynucleotide of claim 9 or 10.

17. A composition comprising a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8, said

SEARCHED  
INDEXED  
COPIED  
FILED

polypeptide being suspended in a pharmacologically acceptable diluent or excipient.

18. A vaccine composition comprising a polypeptide selected from the group consisting of the polypeptide of claims 1, 2, 3, 4, 5, 6, 7, and 8, said polypeptide being present in an amount effective to produce an immune response, and wherein said polypeptide is suspended in a pharmacologically acceptable carrier, diluent or excipient.

- 10 19. A vaccine comprising an immunogenically active amount of the  
composition of claim 17.

- 15 20. A method of vaccinating an animal against infection by a bacterial  
organism selected from the group consisting of streptococcal bacteria and  
staphylococcal bacteria comprising administering to said animal an  
immunologically effective amount of the vaccine of claim 19.

21. The method of claim 20 wherein said animal is a human.

- 20        22. A method of treating a disease comprising administering to an animal afflicted therewith of a therapeutically effective amount of an antibody of claim 12 wherein said antibody is suspended in a pharmacologically acceptable carrier, diluent or excipient.

- 25 23. The method of claim 22 wherein said animal is a human.

24. The method of claim 22 wherein said disease is caused by an organism selected from the group consisting of group A streptococci, group B streptococci, and *Staphylococcus aureus*.

30

add a<sub>2</sub>

35